
CLNN
Clene Inc.
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.9292
Open
3.700
VWAP
3.68
Vol
115.96K
Mkt Cap
32.79M
Low
3.570
Amount
426.32K
EV/EBITDA(TTM)
--
Total Shares
128.43M
EV
39.03M
EV/OCF(TTM)
--
P/S(TTM)
78.79
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. It specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
64.50K
-29.12%
--
--
59.50K
-31.61%
--
--
56.17K
-38.27%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Clene Inc. (CLNN) for FY2025, with the revenue forecasts being adjusted by -2.19% over the past three months. During the same period, the stock price has changed by 20.46%.
Revenue Estimates for FY2025
Revise Downward

-2.19%
In Past 3 Month
Stock Price
Go Up

+20.46%
In Past 3 Month
4 Analyst Rating

680.82% Upside
Wall Street analysts forecast CLNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLNN is 28.50 USD with a low forecast of 20.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy

680.82% Upside
Current: 3.650

Low
20.00
Averages
28.50
High
33.00

680.82% Upside
Current: 3.650

Low
20.00
Averages
28.50
High
33.00
Jones Trading
Justin Walsh
Strong Buy
Initiates
$30
2025-04-23
Reason
Jones Trading
Justin Walsh
Price Target
$30
2025-04-23
Initiates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$31
2025-04-08
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$31
2025-04-08
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$23
2025-04-08
Reason
D. Boral Capital
Jason Kolbert
Price Target
$23
2025-04-08
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$31
2025-03-25
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$31
2025-03-25
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$23
2025-03-24
Reason
D. Boral Capital
Jason Kolbert
Price Target
$23
2025-03-24
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$31
2025-03-24
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$31
2025-03-24
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Clene Inc. (CLNN.O) is -1.77, compared to its 5-year average forward P/E of -6.58. For a more detailed relative valuation and DCF analysis to assess Clene Inc. 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-6.58
Current PE
-1.77
Overvalued PE
1.61
Undervalued PE
-14.77
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-1.42
Current EV/EBITDA
-2.67
Overvalued EV/EBITDA
-0.23
Undervalued EV/EBITDA
-2.60
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
443.34
Current PS
137.73
Overvalued PS
930.53
Undervalued PS
-43.85
Financials
Annual
Quarterly
FY2025Q1
YoY :
+10.96%
81.00K
Total Revenue
FY2025Q1
YoY :
-55.85%
-4.08M
Operating Profit
FY2025Q1
YoY :
-93.22%
-751.00K
Net Income after Tax
FY2025Q1
YoY :
-94.80%
-0.09
EPS - Diluted
FY2025Q1
YoY :
-29.35%
-5.01M
Free Cash Flow
FY2025Q1
YoY :
-3.55%
75.31
Gross Profit Margin - %
FY2025Q1
YoY :
+21.42%
-5.50K
FCF Margin - %
FY2025Q1
YoY :
-93.89%
-927.16
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
9.3K
USD
6
3-6
Months
12.1K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
3
583.4K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
9.3K
USD
6
3-6
Months
12.1K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
3
583.4K
USD
Months
CLNN News & Events
Events Timeline
2025-06-30 (ET)
2025-06-30
08:03:36
Clene provides regulatory update following FDA Type C meeting

2025-05-07 (ET)
2025-05-07
08:07:27
Clene sees cash runway into 3Q25

2025-05-07
08:06:47
Clene reports Q1 EPS (9c), consensus (78c)

Sign Up For More Events
Sign Up For More Events
News
1.0
07-15GlobenewswirePresenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream
4.0
06-30BenzingaD. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target
9.0
06-30NewsfilterClene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
Sign Up For More News
People Also Watch

ATRA
Atara Biotherapeutics Inc
11.580
USD
-5.31%

ANTX
AN2 Therapeutics Inc
1.100
USD
0.00%

WCT
Wellchange Holdings Co Ltd
0.247
USD
+19.86%

DSWL
Deswell Industries Inc
3.088
USD
+1.58%

JG
Aurora Mobile Ltd
11.000
USD
-3.15%

VRME
VerifyMe Inc
0.742
USD
+1.64%

PTLE
PTL Ltd
0.222
USD
0.00%

ZDGE
Zedge Inc
4.250
USD
-8.99%

BGFV
Big 5 Sporting Goods Corp
1.430
USD
+1.42%

HHS
Harte Hanks Inc
3.436
USD
+0.76%
FAQ

What is Clene Inc. (CLNN) stock price today?
The current price of CLNN is 3.65 USD — it has decreased -0.27 % in the last trading day.

What is Clene Inc. (CLNN)'s business?

What is the price predicton of CLNN Stock?

What is Clene Inc. (CLNN)'s revenue for the last quarter?

What is Clene Inc. (CLNN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Clene Inc. (CLNN)'s fundamentals?

How many employees does Clene Inc. (CLNN). have?
